Trial Profile
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced Gradually Progressed NSCLC After First-line Icotinib: an Open-label, Single-arm, Multicenter Phase II Study
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Jan 2018 New trial record